Excision BioTherapeutics
Latest round
- Series A
Last raised
- Feb 2021
Total raised
- $71M
Investors
- 11
About Excision BioTherapeutics
Excision BioTherapeutics Inc.Founded in 2015, Excision BioTherapeutics Inc. is headquartered in San Francisco, US. The company focuses on innovative gene-editing solutions for chronic viral infections.85 mn from the California Institute for Regenerative Medicine.Excision BioTherapeutics, Inc. specializes in developing CRISPR-based therapies that target viral infectious diseases, specifically focusing on human immunodeficiency virus (HIV), herpes simplex viruses (HSV 1&2), and hepatitis B. The company's core product offerings include EBT-101, EBT-104, and EBT-107, designed to leverage proprietary gene-editing technology to potentially cure these chronic infections and improve the quality of life for affected patients. These therapies are currently in various stages of clinical development, with findings and data presented at significant scientific meetings, such as the ASGCT Annual Meeting.Excision BioTherapeutics generates revenue through collaborations and partnerships with leading research institutions and pharmaceutical companies. These strategic alliances facilitate the advancement of its therapeutic products through clinical trials and ultimately to market. While specific pricing plans for its therapies have not been disclosed, revenue is expected to be derived from B2B transactions involving partnerships with healthcare organizations and possibly direct-to-consumer avenues as products gain market approval.Excision BioTherapeutics plans to expand its product pipeline by advancing EBT-101, EBT-104, and EBT-107 through clinical trials.85 mn from the California Institute for Regenerative Medicine, to support these initiatives.
Who invested in Excision BioTherapeutics
11 investors across 3 rounds
See all investors in Excision BioTherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Excision BioTherapeutics
Who invested in Excision BioTherapeutics?
Excision BioTherapeutics has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Excision BioTherapeutics raised?
Excision BioTherapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Excision BioTherapeutics last raise money?
Excision BioTherapeutics's most recent round on record is a Series A, in Feb 2021.
What does Excision BioTherapeutics do?
Excision BioTherapeutics is a biotechnology company.
Where is Excision BioTherapeutics headquartered?
Excision BioTherapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Excision BioTherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Excision BioTherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Excision BioTherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.